Translation of Nanotechnology in Cancer (TONIC)

Research Areas

<table>
<thead>
<tr>
<th>Innovation</th>
<th>Tool Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development</td>
<td></td>
</tr>
</tbody>
</table>

At a Glance

- **Status:** Active Consortium
- **Year Launched:** 2011
- **Initiating Organization:** National Cancer Institute
- **Initiator Type:** Government
- **Location:** North America

Abstract

In 2011, the National Cancer Institute (NCI) initiated a public-private industry partnership called Translation of Nanotechnology in Cancer (TONIC) to accelerate the translation and development of nanotechnology solutions for the early detection, diagnosis, and treatment of cancer. The TONIC consortium, composed of government entities and pharmaceutical, biotechnology, and other healthcare-related companies, works in parallel to the NCI Alliance for Nanotechnology in Cancer. The consortium seeks to evaluate promising nanotechnology platforms and facilitate their successful translation from academic research to the clinic, resulting in safe, timely, effective, and novel diagnosis and treatment options for patients. By encouraging mutual collaborations between Alliance investigators and industry partners on both precompetitive and late-stage programs, TONIC stands to promote the qualification, development, and regulatory acceptance of nanotechnologies in cancer.

Mission

Specifically, the TONIC consortium is tasked with the following:
Translation of Nanotechnology in Cancer (TONIC)

Links/Social Media Feed

Other website  http://nano.cancer.gov/collaborate/collaborating/nanotechnology.asp

Points of Contact

Christopher Hartshorn  
email: christopher.hartshorn@nih.gov

Sponsors & Partners

National Cancer Institute, National Institutes of Health

Updated: 04/07/2016